Recruiting

Windowed Casts

Sponsor:

Southern California Institute for Research and Education

Code:

NCT00446472

Conditions

Diabetic Foot Ulcers

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

Regranex®

Hydrogel

Study Details

Brief summary:

The objective of this study is to compare the effectiveness and safety of windowed casts with Regranex® (topical becaplermin gel) versus placebo (inactive medication) for treatment of diabetic ulcers on the legs and feet.

Conditions

Diabetic Foot Ulcers

Study ID

NCT00446472

Start date

Apr, 2007

Status verified date

Jun, 2010

Completion date

Sep, 2010

Anticipated

Primary completion date

Sep, 2010

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Subject must sign an informed consent
  • Have a history of compliance and reliability in following study required treatment regimen.
  • Have diabetic mellitus Type I or Type II and have a glycohemoglobin Alc less than l0
  • Presence of one or two ulcers in lower extremities

1. Wounds cannot be positioned more than 2.5cm proximal to the malleoli, but may involve any more distal position of the foot
2. Type 2 Diabetic Mellitus Neuropathic ulcers present at least for 3months with failure to heal
3. Post-operation wounds in DM patients with wound present for minimum 4 weeks after surgery and wound surface area has failed to decrease more than 20% in 4 weeks
4. Ulcer(s) must be stage II or III full-thickness (extending through the subcutaneous tissue or beyond - Wagner grade II or III)
5. No joint, tendon or bone exposure
6. Located on the lower extremity.
7. Ulcer size measures 1cm2 < 16 cm2
8. No osteomyelitis affecting the area of the ulcer
9. If two wounds, both can be incorporated into one window when cast applied
  • Adequate foot arterial circulation evidenced by palpable ankle pulses or Doppler with ABI less than or equal to 0.8. If non-compressible, must have triphasic wave Doppler velocity waveforms or toe/brachial pressure greater than or equal to 0.6.

Exclusion criteria:

  • Female subjects who are within child bearing age range.
  • Previous sensitivity to Regranex® Gel.
  • Use of topical antibiotics, enzymatic debriders on the selected ulcer(s) within 30 days preceding randomization.
  • Osteomyelitis affecting the area of the selected ulcer(s)
  • Exposed bone, joint or tendon at ulcer site (Wagner III or higher)
  • Presence of more than two full-thickness ulcers on targeted lower extremity
  • Requirement for systemic antibiotics use within 7 days of study entry
  • Inability to tolerate cast
  • Presence of systemic or local cancer of any kind
  • Life expectancy less than 1 year
  • Subjects with end stage renal failure requiring chronic hemodialysis
  • Concomitant use of Pletal or other vasodilators
  • Ankle Brachial Index less or equal to 0.8 or toe pressure index less than 0.6
  • ESR>20
  • Demonstration of poor compliance including a chronic alcohol, psychiatric condition or drug abuse problems

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: 1

Randomized to Regranex gel

active comparator: 2

Placebo hydrogel will be used for a total of 16 weeks

Interventions

Regranex®

Regranex gel will be used for a total of 16 weeks

Hydrogel

Placebo hydrogel will be applied for 16 weeks

Primary outcome measure

  • Completely healed wounds [ Time Frame: 4 months ]

Central Contacts and Locations

Locations

VA Long Beach Healthcare System

Recruiting

Long Beach, California, United States, 90822

Contacts

Principal Investigator:

Ian Gordon, M.D., Ph.D.

VA Greater Los Angeles Healthcare System

Recruiting

Los Angeles, California, United States, 90073

Contacts

Principal Investigator:

Aksone Nouvong, D.P.M.

More Information

Sponsor

Southern California Institute for Research and Education

Last update posted

Jun 4, 2010

Last verified

Jun, 2010

Keywords

  • diabetes mellitus
  • diabetic neuropathies
  • peripheral vascular diseases

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Southern California Institute for Research and Education on 2010-06-04.